Skip to NavigationSkip to content

prostate cancer

Medical cannabis formulation kills prostate cancer in laboratory tests

Apollon Formularies have announced its medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures in third party independent laboratory testing.

New NICE recommendation for Astellas prostate cancer drug

A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an option for treating hormone-sensitive metastatic prostate cancer (mHSPC) in adults.

An estimated 8,500 men with mHSPC in England, Wales, and Northern Ireland will now have access to the androgen receptor inhibitor, the only oral therapy in the UK that has a licence to treat three distinct types of advanced prostate cancer.

Lucida Medical gains CE marking for AI prostate cancer tech

Image illustrates output by the software

Cambridge-based AI company, Lucida Medical, has received CE marking for its new machine learning-based prostate cancer detection software, Prostate Intelligence (Pi).

Lucida is one of the first companies in the world to commercialise artificial intelligence (AI) software to identify cancer in prostate MRI scans, with the marking enabling the technology to be deployed in the NHS and other European healthcare systems.

Janssen sees promising PRO data for prostate cancer therapy

Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase III TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC), seeing promising results.

The new PRO data showed that the addition of apalutamide to androgen deprivation therapy (ADT) maintained patients’ health-related quality of life (HRQoL) and did not worsen side effect burden, consistent with ADT alone.

Astellas prostate cancer drug gets third approval from MHRA

MHRA sign

The MHRA has approved Astellas Pharma’s XTANDI (enzalutamide) drug for the treatment of a third form of prostate cancer, making it the only oral therapy approved by the agency for three different types of the illness.

AstraZeneca to collaborate with Alchemab on prostate cancer research

AstraZeneca have announced a new collaboration with Cambridge-based biotech company Alchemab, with the aim of accelerating prostate cancer research.

Alchemab and AstraZeneca will work together on a proof-of-concept study to build understanding of the fundamental biology of prostate cancer, with Alchemab’s novel drug discovery platform being used as a diagnostic tool through the identification of disease biomarkers with potential to inform the development of novel antibody-based therapeutics.

Bayer's Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer

The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in men who are at high risk of developing metastatic disease.

Phase 3 data supporting the approval showed that Bayer’s drug, in combination with androgen deprivation therapy (ADT), improved metastasis-free survival by a median of 40.4 months compared to just 18.4 months with placebo plus ADT, meeting the trial’s primary goal.

Prostate Cancer becomes most commonly diagnosed cancer in England

Prostate cancer has overtaken breast cancer to be the most commonly diagnosed cancer for the first time in England, latest figures show.

In 2018, there were nearly 8,000 more cases than in 2017. Overall there were 316,680 cancers diagnosed in 2018, with prostate being the most common type with 49,029 cases, with breast cancer close behind with 47,476 cases.

NHS Scotland recommends Janssen's Zytiga combo for newly diagnosed prostate cancer

Janssen’s Zytiga (abiraterone acetate) has just been approved by the Scottish Medicines Consortium (SMC), meaning that male patients on the NHS in Scotland will now be able to access the drug in combination with prednisone or prednisolone plus androgen deprivation therapy (ADT) for the treatment of newly diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC).

The most common cancer in UK men, there are around 47,000 new cases of prostate cancer in the country every year.

Largest drop ever in US cancer mortality rates, new study shows

The overall cancer mortality rate in the US fell by 2.2% from 2016 to 2017, the largest ever annual decline recorded by the American Cancer Society (ACS).

The study was published this week in A Cancer Journal for Clinicians. It shows that the overall cancer death rate rose in the US until 1991, then fell continuously through to 2017. This resulting in a decline of 29% in cancer mortality rates which translated roughly to 2.9 million less deaths.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches